Trial Profile
A Randomized Phase 2 Study of Rituxan Hycela in Patients With Advanced Melanoma Undergoing Combination Immune Checkpoint Blockade With Nivolumab and Ipilimumab
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Hyaluronidase/rituximab (Primary) ; Hyaluronidase/rituximab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 02 Apr 2024 Planned End Date changed from 31 Oct 2024 to 13 Sep 2024.
- 02 Apr 2024 Planned primary completion date changed from 31 Oct 2023 to 13 Sep 2024.
- 02 Apr 2024 Status changed from recruiting to active, no longer recruiting.